---
title: Current Capacity for Diagnosing Alzheimer's Disease in Germany and Implications
  for Wait Times
date: '2024-09-20'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/39302379/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&fc=20220326224207&ff=20240920192845&v=2.18.0.post9+e462414
source: heidelberg[Affiliation]
description: 'CONCLUSIONS: In spite of having a well-resourced health system, Germany
  is projected to be unable to cope with the demand for biomarker-based AD diagnosis,
  if a disease-modifying AD treatment were introduced. As these treatments might become
  available by the end of 2024, decisive action, in particular dissemination of high-performing
  AD blood tests for triage in primary care, will be needed to prevent delays in access
  and potentially avoidable and inequitable disease ...'
disable_comments: true
---
CONCLUSIONS: In spite of having a well-resourced health system, Germany is projected to be unable to cope with the demand for biomarker-based AD diagnosis, if a disease-modifying AD treatment were introduced. As these treatments might become available by the end of 2024, decisive action, in particular dissemination of high-performing AD blood tests for triage in primary care, will be needed to prevent delays in access and potentially avoidable and inequitable disease ...